Mast cell differentiation in vitro is accompanied by large-scale phenotypic changes as progenitors become IgE receptor-positive, granulated mast cells. Many of the phenotypic changes occur by expression of gene products unique to mast cells and basophils. Although these features make for an attractive model system for studies of cellular differentiation, the lack of a defined progenitor for mast cells (most investigators use unfractionated bone marrow) and the use of IL-3 to generate long term mast cell cultures has not allowed for a narrowly-focused window on the phenotypic changes. We have defined a late, committed stage in the differentiation of the mast cell progenitor just prior to granulation. This mast cell-committed progenitor does not require IL-3 of differentiation but does require factors provided by fibroblasts from connective tissue such as embryonic skin. This model system provides unique advantages to analyze mastocytogenesis, a process important in the development of diseases of immediate hypersensitivity. First, the in vitro differentiation system will be used to follow discrete changes in late-stage progenitor cells responding to defined factors. Preparations of isolated mast cell-committed progenitors will be phenotyped and triggered with purified fibroblast-derived factor. Cell activation will be monitored by following the mobilization of intracellular calcium and incorporation of tritiated thymidine. Changes in expression of high affinity IgE receptors, growth factor receptors, histamine biosynthesis, and granule assembly will correlate in sequence with signal transduction. Second, the differentiation system will be adapted for rat studies in order to detect chymase, RMCP-II, carboxypeptidase A, or heparin proteoglycan in mast cells derived from culture on embryonic skin monolayers. This will allow us to study mast cell heterogeneity (mucosal vs connective tissue type) in an in vitro system. Third, the factors which cause the transition of the primitive bone marrow progenitor for mast cells to progress to the IL-3 independent committed progenitor will be determined by experiments designed to mimic in vitro the two most likely in vivo milieus that give rise to the committed progenitor: completely degranulated mast cells from the gut mucosa draining into the MLN, or bone marrow progenitors trafficking to the MLN as a primitive progenitor and progressing into committed progenitors in situ.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Modified Research Career Development Award (K04)
Project #
Application #
Study Section
Immunological Sciences Study Section (IMS)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Virginia Commonwealth University
Schools of Medicine
United States
Zip Code